Bupropion: a new treatment for smokers
- 8 July 2000
- Vol. 321 (7253) , 65-66
- https://doi.org/10.1136/bmj.321.7253.65
Abstract
Footnotes JB has been reimbursed by GlaxoWellcome, the manufacturer of bupropion, for attending international conferences in respiratory medicine and is participating in a clinical trial of transdermal nicotine funded by Pharmacia and Upjohn. MJJ has received honorariums from GlaxoWellcome for speaking and attending meetings of advisory panels.Keywords
This publication has 6 references indexed in Scilit:
- Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectivenessThe Lancet, 1999
- A Controlled Trial of Sustained-Release Bupropion, a Nicotine Patch, or Both for Smoking CessationNew England Journal of Medicine, 1999
- Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism∗The British Journal of Psychiatry, 1999
- Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Health Educational Authority.1998
- A Comparison of Sustained-Release Bupropion and Placebo for Smoking CessationNew England Journal of Medicine, 1997
- Bupropion: a review of its mechanism of antidepressant activity.1995